Ankylosing Spondylitis Clinical Trial
Official title:
Research Asistant in Deparment of Nursing
This study was carried out to develop mobile application on the android platform for the
subcutaneous anti-TNF drug adherence of ankylosing spondylitis patients and to evaluate the
effect of this application on drug compliance.
The universe of this experimental designed posttest control group research is consisted of
patients prescribed subcutaneous anti-TNF drug due to ankylosing spondylitis in Eskişehir
Osmangazi University Health, Application and Research Hospital Rheumatology Polyclinic
between 15 December 2017 - 30 June 2019. The patients who constituted the sample of the study
were assigned by lot to mobile application and the education booklet groups. The mobile
application that includes follow-up and information related to disease information, anti-TNF
drug application and management was transferred to mobile phones of patients in mobile
application group via bluetooth technology and installed. The patients in the education
booklet group were given an education booklet on disease information, antiTNF drug
administration and management. In the study, patients were evaluated once before anti-TNF
drug treatment and every 6 weeks during 6 months (4 times) after treatment. The data of the
study were collected by means of an individual identification form, BASDAI, BASFI, ASQoL and
Subcutaneous Anti-TNF Treatment Adherence Questionnaire.
Ankylosing spondylitis is a chronic, inflammatory disease that affects the axial spine,
causing progressive limitation on the spine and leading to a decrease in quality of life.
Anti TNF drugs are frequently used in the treatment of ankylosing spondylitis and teaching
activities in improving patient compliance and patient compliance are very important in the
success of this treatment. This study was carried out to develop mobile application on the
android platform for the subcutaneous anti-TNF drug adherence of ankylosing spondylitis
patients and to evaluate the effect of this application on drug compliance.
The universe of this experimental designed posttest control group research is consisted of
patients prescribed subcutaneous anti-TNF drug due to ankylosing spondylitis in Eskişehir
Osmangazi University Health, Application and Research Hospital Rheumatology Polyclinic
between 15 December 2017 - 30 June 2019. The patients who constituted the sample of the study
were assigned by lot to mobile application and the education booklet groups. The mobile
application that includes follow-up and information related to disease information, anti-TNF
drug application and management was transferred to mobile phones of patients in mobile
application group via bluetooth technology and installed. The patients in the education
booklet group were given an education booklet on disease information, antiTNF drug
administration and management. In the study, patients were evaluated once before anti-TNF
drug treatment and every 6 weeks during 6 months (4 times) after treatment. The data of the
study were collected by means of an individual identification form, BASDAI, BASFI, ASQoL and
Subcutaneous Anti-TNF Treatment Adherence Questionnaire.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
| Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
| Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
| Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
| Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
| Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
| Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
| Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
| Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
| Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
| Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
| Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
| Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
| Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
| Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
| Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
| Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
| Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |